Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P93
Near historical high
vs 2Y Ago
2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 89.78% |
| Q3 2025 | -3.13% |
| Q2 2025 | 4.34% |
| Q1 2025 | 10.14% |
| Q4 2024 | 6.23% |
| Q3 2024 | 0.57% |
| Q2 2024 | -3.99% |
| Q1 2024 | 24.73% |
| Q4 2023 | 44.34% |
| Q3 2023 | -8.46% |
| Q2 2023 | -19.55% |
| Q1 2023 | 130.82% |
| Q4 2022 | -36.68% |
| Q3 2022 | 187.77% |
| Q2 2022 | -33.35% |
| Q1 2022 | 5.75% |
| Q4 2021 | -52.72% |
| Q3 2021 | 5.47% |
| Q2 2021 | -2.23% |
| Q1 2021 | 21.19% |
| Q4 2020 | -12.50% |
| Q3 2020 | 21.70% |
| Q2 2020 | 56.06% |
| Q1 2020 | 1.17% |
| Q4 2019 | -11.49% |
| Q3 2019 | 46.18% |
| Q2 2019 | 87.85% |
| Q1 2019 | 0.00% |